Exosome therapy developer Codiak Biosciences – based on research at Gothenburg and MD Anderson Cancer Center – has filed to raise up to $100m.

Codiak Biosciences, a US-based exosome drug developer, refiled for an initial public offering on Wednesday. The company had previously filed to raise up to $86.3m in an offering on the Nasdaq Global Select Market in April 2019 before withdrawing its application three months later. It has now set an initial target of $100m for an…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.